In clinical practise, Tolperisone hydrochloride, (Muscalm) a central muscle relaxant drug, is administered to patients with spasticity of the neck and shoulder muscles.
The antivertiginous effects of Tolperisone were evaluated in a single controlled study in 29 patients who had vertigo and/or dizziness, especially that due to cervical vertigo, head injuries, and the traumatic cervical syndrome. The clinical signs and symptoms in these patients were evaluated at two points of time both by the physicians and the patients themselves. The objective symptoms in terms of equilibrium and auditory functions were evaluated firstly before treatment and secondly after medication by the same doctors.
The drug dosage was 300mg of Tolperisone daily for four or six weeks.
The global, comparative judgment of the subjective and objective clinical findings showed antivertiginous drug effects in 20 out of the 29 patients (69.0%) after four or six weeks of medication.
With respect to antivertiginous effects of this drug, vertigo and/or dizziness were particularly suppressed in 23 out of the 29 patients (79.3%), especially in cervical vertigo.
No side-effects were observed during the treatment. Therefore, the authors concluded that Tolperisone had antivertiginous effects in patients with cervical vertigo and head and neck injuries.
View full abstract